Dr. Parkes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Amgen - Corporate Headquarters
1 Amgen Center Dr
Thousand Oaks, CA 91320
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
- Massachusetts General HospitalResidency, Internal Medicine, 2012 - 2015
- University of Wisconsin School of Medicine & Public HealthClass of 2012
Certifications & Licensure
- WI State Medical License 2017 - 2025
- TX State Medical License 2016 - 2020
- MA State Medical License 2012 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.Sailaja Kamaraju, Amy M Fowler, Sergey Tarima, Lubna N Chaudhary, Mark E Burkard
Clinical Breast Cancer. 2024-12-10 - Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE) Immunotherapy in Adult Patients with Previous...Mukul Minocha, Corbin G Thompson, Alexis Murphy, Yanchen Zhou, Christian Brandl
Clinical Pharmacokinetics. 2024-12-01 - 2 citationsSustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, Maria Eugenia Olmedo, Michael Boyer
Journal of Clinical Oncology. 2024-10-10
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: